Kyle Vaughn Laster

机构：China-US (Henan) Hormel Cancer Institute · ORCID：0000-0002-8469-0015

发表论文 52 篇 · 总被引 801 次 · h-index 17

代表论文

• Cdc2-like kinases: structure, biological function and therapeutic targets for diseases (2023 · Signal Transduction and Targeted Therapy · 被引 69)
• Costunolide is a dual inhibitor of MEK1 and AKT1/2 that overcomes osimertinib resistance in lung cancer (2022 · Molecular Cancer · 被引 61)
• Targeting CRAF kinase in anti-cancer therapy: progress and opportunities (2023 · Molecular Cancer · 被引 38)
• The comparison of cancer gene mutation frequencies in Chinese and U.S. patient populations (2022 · Nature Communications · 被引 35)
• A novel lncRNA MTAR1 promotes cancer development through IGF2BPs mediated post-transcriptional regulation of c-MYC (2022 · Oncogene · 被引 30)
• Novel dual inhibitor for targeting PIM1 and FGFR1 kinases inhibits colorectal cancer growth in vitro and patient-derived xenografts in vivo (2022 · Acta Pharmaceutica Sinica B · 被引 26)